Epithalon

The Epithalon evidence base cited here is 12 sources — 1 clinical, 9 preclinical, 1 review. Its strongest evidence is human — a clinical study, most recently 2024 ("Improving Biological Age, Telomere Length, and Cognition: A Case Study"). Regulatory status: Not FDA-approved.

• Epitalon (Epithalon, sequence Ala-Glu-Asp-Gly) is a synthetic tetrapeptide based on the natural pineal peptide epithalamin, developed by Russian researcher Vladimir Khavinson and studied for over 35 years.
• Its headline mechanism is telomerase activation — reported at extraordinarily low concentrations (10⁻¹⁷–10⁻¹⁵ M) — alongside pineal/melatonin regulation and epigenetic gene-expression effects.
• A central, practical caveat: widely circulated Western dosing (5–10 mg) appears to be 50–100× higher than necessary, likely from translation errors of the original Russian microgram-dose research. Biological saturation means more is not better.

Epitalon is a four-amino-acid peptide modeled on epithalamin, a regulatory peptide from the pineal gland. It is the most-studied compound in the 'bioregulator' tradition pioneered by Vladimir Khavinson, researched primarily for anti-aging via telomere maintenance and circadian/melatonin support.

It is investigational outside Russia, not FDA-approved, and everything below is research context rather than medical guidance.

Epitalon is a synthetic tetrapeptide — Ala-Glu-Asp-Gly, just 4 amino acids, ~390 Da — making it one of the smallest peptides in research use. It is a synthetic analog of the natural pineal peptide epithalamin.

Its small size and the fact that it acts at femto- to picomolar concentrations are central to the dosing debate below: a peptide active at 10⁻¹⁵ M does not need milligram dosing to saturate its effect.

Epitalon is reported to activate telomerase — the enzyme that maintains the protective telomere caps on chromosomes — at extremely low concentrations, which in cell studies extended replicative lifespan. It also stimulates pineal melatonin production (supporting circadian rhythm), appears to modulate gene expression epigenetically, and has been linked to enhanced antioxidant-enzyme activity. These are largely cell-culture and animal findings; the human anti-aging claim remains inferential.

This is the single most important practical point about epitalon. The original Russian research demonstrating effects used MICROgram doses, but much of the Western anecdotal protocol space recommends 5–10 MILLIgram doses — roughly 50–100× higher — apparently due to unit/translation errors. Because epitalon acts at saturating concentrations far below those levels, the higher doses are unlikely to add benefit and simply increase exposure.

• Evidence-aligned range: ~100–500 mcg daily subcutaneously (≈300 mcg matches Russian clinical equivalents)
• Animal lifespan studies that reported ~25–33% extension used ~30–40 µg/kg — microgram, not milligram, dosing
• Use a small (e.g. 0.3 mL) insulin syringe for accurate microgram dosing
• Effects from corrected microgram dosing should be comparable to high-dose protocols due to biological saturation

If a protocol tells you to inject 5–10 mg of epitalon, treat that as a likely translation artifact and verify against the original Russian microgram research.

• Reconstitute with bacteriostatic water down the vial wall; swirl gently, don't shake; solution should be clear and colorless.
• For accurate microgram dosing, reconstitute to a known concentration (e.g. a 10 mg vial + 5 mL = 2 mg/mL, so 0.1 mL = 200 mcg) and use a small syringe.
• Refrigerate immediately; discard if the powder is discolored or the solution turns cloudy.

Reported as well-tolerated, with mild injection-site reactions and vivid dreams (consistent with melatonin effects) the most common notes; no severe adverse events have been reported across 30+ years of Russian clinical use. The main theoretical concern is telomerase activation in the context of cancer — it is generally avoided with active malignancy. Adopting corrected microgram dosing also reduces unnecessary exposure relative to the inflated Western protocols.

• Telomerase activation in human fibroblasts (2003): 0.1 µM extended replicative lifespan from 34 to 44+ passages.
• Neurogenesis gene expression (2020, human stem cells): 0.01 µg/mL upregulated neurogenic markers (Nestin, GAP43, β-Tubulin III) ~1.6–1.8 fold — note the very low effective concentration.
• Retinal degeneration / AMD (2019, human): 5 µg/eye over 10 days, with a high reported positive-response rate and improved visual acuity.

Epitalon is not FDA-approved in the US and is sold as a research chemical for laboratory use only, not intended for human consumption. It has a long history of clinical use in Russia.

On the Huberman Lab podcast, Dr. Abud Bakri situated epitalon within Vladimir Khavinson's Soviet 'bioregulator' tradition. The finding he highlighted: epitalon restores melatonin production in aged (but not young) animals and humans, and is tied to a ~15-year nursing-home cohort in which an epitalon-plus-thymalin group showed lower mortality from cardiovascular disease, infection, and cancer.

Two honest caveats he and Dr. Huberman returned to: this is largely Russian-authored data without the replicated, gold-standard Western trials, and the family's 'short peptide assists gene transcription' mechanism is not well established in mainstream molecular biology. Dr. Huberman also mentioned a research interest in epitalon's possible retinal/melanopsin effects from his own former lab focus — an unproven hypothesis, not a clinical claim.

Russian-tradition evidence and expert commentary — promising, but not independently confirmed at Western trial standards.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.